Abstract
The purpose of this study was to evaluate the impact of intestinal efflux transporters on the in vivo oral absorption process. Three model drugs (fexofenadine (FEX), sulfasalazine (SASP), and topotecan (TPT)) were selected as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and P-gp and BCRP substrates, respectively.
The drugs were orally administered to portal vein cannulated rats after pretreatment with zosuquidar (ZSQ), P-gp inhibitor, and/or Ko143, BCRP inhibitor. Intestinal availability (Fa·Fg) of the drugs was calculated from the difference between portal and systemic plasma concentrations. When rats were orally pretreated with ZSQ, Fa·Fg of FEX increased 4-fold and systemic clearance decreased to 75% of the control. In contrast, intravenous pretreatment with ZSQ did not affect Fa·Fg of FEX, although systemic clearance decreased significantly. These data clearly show that the method presented herein using portal vein cannulated rats can evaluate the effects of intestinal transporters on Fa·Fg of drugs independently of variable systemic clearance. In addition, it was revealed that 71% of FEX taken up into enterocytes underwent selective efflux via P-gp to the apical surface, while 79% of SASP was effluxed by Bcrp. In the case of TPT, both transporters were involved in its oral absorption. Quantitative analysis indicated a 3.5-fold higher contribution from Bcrp than P-gp. In conclusion, the use of of various drugs via their transport back to the apical surface (Thiebaut et al., 1987, and Schinkel et al., 2003) .
In the drug discovery stage, new chemical entities (NCEs) often suffer from poor systemic exposure due to the limited gastrointestinal absorption via these efflux transporters. Whether NCEs are subject to active efflux by one or both transporters can be evaluated by using Caco-2 cell lines and/or Madin-Darby canine kidney (MDCK) cell lines transfected with individual efflux transporter genes (Troutman et al., 2003) .
However, it is difficult to predict the intestinal availability (Fa·Fg) of NCEs from those in vitro experiments because the in vivo absorption process from the GI tract is restricted not only by intestinal efflux transporters but also other factors, including solubility, membrane permeability or metabolism. In addition, a method to
quantitatively assess the impact of these transporters on the in vivo absorption process has not been fully established.
To investigate the effects of intestinal efflux transporters on oral drug absorption, co-administration studies with transporter inhibitors are often carried out in vivo using experimental animals (Bardelmeijer et al., 2004, and Takeuchi et al., 2008) . In this approach, to calculate oral bioavailability (F), not only oral administration but also intravenous injection study should be performed. Then, Fa·Fg is obtained by dividing oral F by hepatic availability (Fh) (Kato et al., 2003) , where the renal clearance should be estimated to calculate Fh. If the systemic clearance of the test compound is significantly affected by oral pretreatment with the transporter inhibitor, intravenous studies should be conducted at each inhibitor dose.
Transporter gene knockout mice and rats are also used to assess the effects of transporters (Chen et al., 2009, and Zamek-Gliszczynski et al., 2012) , however a general concern in the use of knockout animals for pharmacokinetic studies is the potential compensatory effects from up-or down-regulation of other transporters and drug metabolism-related genes. Alteration of mRNA levels of several transporter and metabolism-related genes was reported in Abcb1 and Abcg2 knockout mice and rats (Cisternino et al., 2004, and Chu et al., 2012) . On the other hand, Agarwal et al. (2012) (Matsuda et al., 2012) . Calculation of Fa·Fg using portal vein cannulated rats shows less variability than conducting typical kinetic analyses because our calculation method is less sensitive to inter-individual fluctuation in portal blood flow. In addition, since systemic clearance, renal clearance, and Fh are not necessary to calculate Fa·Fg, our method is considered to be highly applicable to transporter inhibition studies.
In this study, the impact of intestinal efflux transporters on oral absorption of 3 model drugs, fexofenadine (FEX), sulfasalazine (SASP) and topotecan (TPT), was evaluated.
FEX, a non-sedating histamine H1 receptor antagonist, is well-known as a substrate for OATP1A2 and OATP2B1 as well as P-gp (Cvetkovic et al., 1999) . anti-inflammatory drug, shows low intestinal absorption due to low solubility and permeability. The bioavailability of SASP in Abcg2 deficient mice and rats was 9-and 17-fold higher, respectively, than that of wild-type (Zaher et al., 2006 and Huang et al., 2012) . In addition, co-administration of SASP and curcumin, a BCRP inhibitor, increased SASP exposure 3-fold in humans (Kusuhara et al., 2012) , suggesting that BCRP-mediated efflux limits intestinal absorption of SASP. The anti-cancer drug TPT is reported to be a good substrate for BCRP and a weaker substrate for P-gp (Hendricks et al., 1992 and Maliepaard et al., 1999 (Yamasaki et al., 2010) .
Zosuquidar (ZSQ) and Ko143 are used as selective inhibitors of P-gp and BCRP.
ZSQ is reported to be an extremely potent P-gp inhibitor and does not modulate BCRP-mediated resistance (Shepard et al., 2003) , while Ko143 is also well-known as a potent BCRP inhibitor (Allen et al., 2002 Charles River Laboratory Japan (Yokohama, Japan) and were kept in an experimental animal room with an ambient temperature of 22-24˚C and a 12-h light-dark cycle for 6 days before use. The cannulated rats were shipped to our lab from Charles River Laboratory Japan 2 days after the surgical procedure and arrived the next day. The oral and intravenous administration studies were conducted on the 9th day after the surgery.
At 9 th day, there observed no significant differences in the physiological condition of cannulated and untreated rats (Matsuda et al., 2012) .
Surgical procedure for portal vein cannulation. The surgical procedure for insertion of catheter was used our reported techniques, previously (Matsuda et al., 2012) .
Animals were implanted with catheters in the portal vein as follows. Rats were anaesthetized with ketamine (42.9 mg/kg) and xylazine (8.2 mg/kg) administered intraperitoneally. A mid-line incision 1-2 cm was made in the abdominal cavity and the portal vein was detached near the liver. To prevent bleeding, the portal vein was ligated temporarily as the catheter was inserted. The catheter (3.5Fr polyurethane tube, Access™ technologies Inc.) was inserted immediately and fixed by a purse-string suture on the portal vein. The time to reperfusion was about 1 min after intercepted blood flow.
This method for insertion of catheter can avoid the occlusion of the vessel. In addition, a catheter with trumpet-shaped opening was used to prevent the catheter from slipping out of the vessel with minimizing the effect on blood flow. Another end of the catheter was passed subcutaneously to the dorsal base of the neck and the laparotomy was closed in two layers, with a 4/0 silk blade to the muscle, and a surgical clip to close the skin. was calculated using eq. (1):
where Q por , R b , AUC por and AUC sys were the portal blood flow, the blood / plasma concentration ratio, AUC calculated from plasma concentration in the portal vein and the systemic circulation, respectively. As Q por, the value of 32.9 mL/min/kg was used that was calculated in our previous report by assuming that Fa·Fg of antipyrine was 1 (Matsuda et al., 2012) .
Statistics.
The presented values were all mean ± S.D. As shown in Fig. 6 , the Fa·Fg after pretreatment with ZSQ+Ko143 was regarded as a fraction of the dose influxed into enterocytes since all 3 drugs were reported to be hardly metabolized (Das et al., 1979 , Herben et al., 1997 , and Strelevitz et al., 2005 . In FEX and SASP, a fraction of the efflux by P-gp or Bcrp was calculated as the difference between the Fa·Fg in ZSQ+Ko143 pretreated rats and that of control rats. Thus, the fractions of influx, efflux and Fa·Fg in control rats were calculated as 0.77, 0.55 and 0.22 for FEX, and 0.14, 0.11 and 0.03 for SASP, respectively.
In the case of TPT, the contribution of each transporter was calculated by equations (Table 1) . Similarly, Adane et al. (2012) reported alteration of the systemic AUC of a camptothecin analogue in oral and intravenous administration studies following oral pretreatment with ZSQ or Elacridar, a dual P-gp and Bcrp inhibitor. In these cases, to consider the effect of transporters on oral absorption of FEX or camptothecin, not only systemic but also renal clearance should be estimated since P-gp and Bcrp are expressed in the renal tubule.
In this study using portal vein cannulated rats, changes in Fa·Fg of FEX after oral and intravenous pretreatment with ZSQ were estimated (Fig. 1) . Oral administration of ZSQ was considered to inhibit both systemic and intestinal P-gp, while intravenous administration of ZSQ inhibited only systemic P-gp expressing in liver, kidney, and other organs except for intestine. Fa·Fg of FEX after oral administration of ZSQ was 4-fold higher than control, but was almost the same as control after intravenous administration despite a significant change in systemic clearance. The change in systemic clearance is negligible because the absorbed amount is calculated from the difference between the systemic and portal amount in eq. (1). These results clearly show
that our method using portal vein cannulated rats enables the evaluation of the effects of selective inhibitors on oral absorption of substrate drugs independently of variable systemic clearance, without the requirement of an intravenous administration study.
As shown in Fig. 3 , Fa·Fg of TPT did not increase at higher inhibitor doses, which might be attributed to the complete inhibition of P-gp-and Bcrp-mediated intestinal efflux by ZSQ (30 mg/kg) and Ko143 (10 mg/kg). Poller et al. (2011) reported that TPT transport in a double-transfected MDCKΙΙ-ABCB1 / ABCG2 cell line treated with 1.6 µM and 500 µM TPT was completely blocked in the presence of ZSQ (5 µM) and Ko143 (1 µM). Chemical knockdown with ZSQ and Ko143 was therefore assumed to almost completely inhibit the intestinal efflux transporter. In addition, ZSQ was reported to have a much lower affinity for CYP3A than for P-gp (Dantzig et al., 1999) . In our preliminary study, Fa·Fg of felodipine, a drug easily metabolized at the intestine (Wang et al., 1989) , did not change after pretreatment with ZSQ or Ko143 (data not shown),
suggesting that intestinal metabolism was not affected by ZSQ (30 mg/kg) and Ko143
(10 mg/kg), although FEX, SASP and TPT were resistant to oxidative metabolism.
In order to understand the impact of P-gp and Bcrp quantitatively, the contributions of enterocyte efflux transporters to overall absorption were represented as dose fraction, shown in Fig. 6 . In the case of FEX, 71% of the amount taken up into enterocytes was
effluxed to the apical surface by P-gp in rats. This result is in good agreement with results using Caco-2 cell monolayers reported by Petri et al. (2004) in which P-gp attenuated the permeability of FEX to 30%. Also, our results indicated that 77% of orally administered FEX was taken up into enterocytes despite its large polar surface area and high molecular weight. Qiang et al. (2009) reported that pretreatment with fluvastatin, a substrate of OATP1B1, OATP2B1 and OATP1B3 (Noé et al., 2007) , decreased the bioavailability of FEX 0.45-fold in rats due to reduced intestinal absorption of FEX rather than enhanced systemic elimination. Accordingly, our results suggest that FEX cellular uptake might be moderated by rat Oatps.
SASP was found not to be a substrate of P-gp; however, 79% of that taken up by enterocytes was effluxed to the apical surface by Bcrp, resulting in a very low Fa·Fg of only 0.03 in the control study. Additionally, low solubility and low permeability contributed to the low oral absorption of SASP. While the solubility of SASP is 0.0024 mg/mL in water (Benet et al., 2011) , the concentration of SASP in the drug solution was
both transporters results in a dramatic increase. This unexpected effect has led to postulation of a synergistic role for P-gp and Bcrp (Polli et al., 2009 ). However, using a blood-brain barrier kinetic model, Kodaira et al. (2010) analyzed brain uptake of these drugs and proposed a kinetic concept for this apparent synergism. They demonstrated that P-gp involved in the efflux of these drugs together with Bcrp attenuates the effect of Bcrp impairment on drug concentrations in the brain. That is, two efflux transporters act as a safety net that prevents brain penetration of common substrates when another efflux transporter is dysfunctional. Intestinal absorption of TPT was also restricted by both P-gp and Bcrp. As shown in Fig. 6 , 70% of TPT taken up into enterocytes was effluxed to the apical surface by P-gp and Bcrp, and Bcrp-mediated efflux was 3.5-fold higher than that of P-gp. Li et al. (2008) Each symbol represents the mean ± S.D. for 3 to 5 rats. Values represent the mean ± S.D. for 3 to 5 rats. Statistically significant difference: *, P < 0.05, **, P < 0.01, ***, P < 0.001, control versus ZSQ, Ko143 or ZSQ+Ko143; ‡, P < 0.05, ‡ ‡, P < 0.01, ‡ ‡ ‡, P < 0.001, ZSQ versus Ko143; #, P < 0.05, ##, P < 0.01, ###, P < 0.001, ZSQ versus ZSQ+Ko143; † † †, P < 0.001, Ko143 versus ZSQ+Ko143.
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